CD8A and neoplasm: This was due to the fact that the tumour volume after treatment with US+CA with the addition of CD4+ and CD8+ T cell-depleting antibodies was similar to tumours treated with US+CA plus only CD8+ T cell-depleting antibodies, but both groups had a 3-fold higher tumour volume than US+CA-treated tumours that did not receive T cell depleting antibodies [42].